Valuation: Biocept Inc

Market Cap 110K 95.26K 89.51K 81.41K 153K 10.55M 156K 1.05M 410K 5.28M 414K 405K 17.55M P/E 2021
-18.9x
P/E 2022 -0.28x
Enterprise Value -678K -585K -550K -500K -940K -64.8M -956K -6.44M -2.52M -32.45M -2.54M -2.49M -108M EV / Sales 2021
0.73x
EV / Sales 2022 0.32x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Change 5-day change 1-year change 3-year change Capi.($)
+115.22%-40.88% - - 262
-1.46%-6.69%+167.00%+347.13% 21.1B
+0.14%+0.34%-41.94%-21.36% 9.96B
-3.54%+7.80%+319.84%+17.15% 7.31B
+0.01%0.00%+86.32%+51.28% 6.59B
-1.71%-4.13%-40.27% - 6.16B
+3.22%+6.11%-12.93%-8.79% 5.97B
+1.19%+0.81%+81.12%+106.81% 4.55B
-0.64%-1.30%-11.45%-17.57% 4.27B
+3.92%+3.82%-19.12%-32.61% 2.85B
Average +11.64%+0.69%+58.73%+55.25% 7.64B
Weighted average by Cap. -0.47%-0.93%+86.57%+125.24%

Financials

2021 2022
Net sales 61.25M 52.9M 49.71M 45.21M 85M 5.86B 86.4M 582M 228M 2.93B 230M 225M 9.75B 25.86M 22.33M 20.99M 19.09M 35.88M 2.47B 36.48M 246M 96.15M 1.24B 97.08M 94.98M 4.11B
Net income -2.82M -2.44M -2.29M -2.08M -3.92M -270M -3.98M -26.86M -10.5M -135M -10.6M -10.37M -449M -32.09M -27.71M -26.04M -23.68M -44.53M -3.07B -45.26M -305M -119M -1.54B -120M -118M -5.11B
Net Debt -16.19M -13.98M -13.14M -11.95M -22.47M -1.55B -22.84M -154M -60.2M -775M -60.79M -59.47M -2.58B -788K -681K -640K -582K -1.09M -75.35M -1.11M -7.49M -2.93M -37.73M -2.96M -2.89M -125M
Logo Biocept Inc
Biocept, Inc. is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. The Company has developed a patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, it is a commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample. The Company operates a clinical laboratory and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. The assays the Company offers are classified as laboratory developed tests (LDT) under the CLIA regulations. The Company’s assays, performed on cerebral spinal fluid, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease.
Employees
-